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Abstract
Background: Recent genome-wide association studies have identified several genetic loci linked to coronary artery
disease (CAD) and myocardial infarction (MI). The 9p21.3 locus was verified by numerous replication studies to be
the first common locus for CAD and MI. In the present study, we investigated whether six single nucleotide
polymorphisms (SNP) rs1333049, rs1333040, rs10757274, rs2383206, rs10757278, and rs2383207 representing the
9p21.3 locus were associated with the incidence of an acute MI in patients with the main focus on the familial
aggregation of the disease.
Methods: The overall cohort consisted of 976 unrelated male patients presenting with an acute coronary
syndrome (ACS) with ST-elevated (STEMI) as well as non-ST-elevated myocardial infarction (NSTEMI). Genotyping
data of the investigated SNPs were generated and statistically analyzed in comparison to previously published
findings of matchable control cohorts.
Results: Statistical evaluation confirmed a highly significant association of all analyzed SNP’s with the occurrence of
MI (p < 0.0001; OR: 1.621-2.039). When only MI patients with a positive family disposition were comprised in the
analysis a much stronger association of the accordant risk alleles with incident disease was found with odds ratios
up to 2.769.
Conclusions: The findings in the present study confirmed a strong association of the 9p21.3 locus with MI
particularly in patients with a positive family history thereby, emphasizing the pathogenic relevance of this locus as
a common genetic cardiovascular risk factor.
Background
In recent years, genome-wide association studies
(GWAS) have displayed an effective approach to localize
genomic regions predisposing to common, polygenetic
disorders, including cardiovascular disorders [1,2]. By
means of independent genome-wide association studies
using single nucleotide polymorphism (SNP) arrays the
first common chromosomal locus has been identified
which confers susceptibility for coronary artery disease
(CAD) and myocardial infarction (MI) [3-5]. Initially,
the two SNPs rs10757274 and rs2383206 consistently
associated with CAD were identified in a large scale
study population of Caucasian origin [3]. Both poly-
morphisms are located within a locus spanning a 58-
kilobase region on chromosome 9p21.3. Three addi-
tional SNPs, rs1333040, rs2383207, and rs10757278 on
the 9p21.3 locus and in genetic disequilibrium were
identified independently as being associated with MI [4].
Moreover, large-scale genome-wide association scans
identified further polymorphisms, amongst others
rs1333049, within the same genomic region to be
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chromosome 9p21.3 as a susceptibility locus for the
incidence of the disease [5,6]. Based on these findings,
replication studies using case-control designs proved
that the identified SNPs were associated with CAD and
MI in a large variety of study population [7-17]. In all
studies, the association of the 9p21.3 locus with CAD
and MI was shown to be independent of conventional
risk factors. In a subsequent study the association of the
rs1333049 risk variant with the extend of CAD could be
established [18]. Thus, even though the responsible gene
in this region is still unknown, the 9p21.3 locus was ver-
ified to be the first common genetic factor affecting the
r i s ko fC A Da n dM I .F u r t h e rs t u d i e sm a yp r o v i d en e w
insights into the impact of chromosome 9p21.3 on the
pathogenesis of CAD and the occurrence of a MI.
In the present study the influence of six SNPs
(rs1333049, rs1333040, rs10757274, rs2383206,
rs10757278, and rs2383207) representing the 9p21.3
region on the occurrence of MI was investigated. The
main focus of our investigation was on an association of
t h e9 p 2 1 . 3l o c u sw i t hap o s i t i v ef a m i l yh i s t o r yo fM Ii n
a large cohort of patients presenting with an acute cor-
onary syndrome (ACS).
Methods
Study subjects
Over a three year span (2004 to 2006), a total of 976 unre-
lated male patients younger than 65 years were enrolled
into a study due to a symptomatic ACS with STEMI as
well as NSTEMI. This prospective multi-centre registry
involved four heart centres and six cardiologic depart-
ments in Germany. The study was approved by the ethical
committee of the University Witten/Herdecke, Germany,
and conformed to the declaration of Helsinki. All partici-
pants gave written informed consent to participation.
MI was defined as follows: ischemic type chest pain
lasting for more than 20 minutes, at least 0.1 mV of ST-
segment elevation in the limb leads and/or at least 0.2
mV elevation in the precordial leads and one of the fol-
lowing criteria: left bundle branch block, new Q wave (at
least 0.03 s), elevated creatine kinase or positive troponin
T or I. All cases underwent cardiac catheterization and
interventional or surgical revascularization. Patients < 18
and > 65 years, with unstable angina or without central
European origin were excluded from further studies.
Blood samples and DNA preparation
EDTA-blood samples were drawn from each participant
at baseline ward round. Genomic DNA was extracted
from 350 μl of these samples using the BioRobot EZ1
and the EZ1 blood extraction kit according to the man-
ufacturer’s instructions (QIAGEN; Hilden, Germany).
DNA was quantified using the BioPhotometer
(Eppendorf; Hamburg, Germany) and each sample was
diluted to a final concentration of 25 ng/μl.
PCR amplification and genotyping
Genotyping of the investigated SNPs (rs1333049,
rs1333040, rs10757274, rs2383206, rs10757276, and
rs2383207) was carried out by real time PCR and subse-
quent melting curve analysis on a LightCycler 480
instrument (Roche Applied Science; Mannheim, Ger-
many). The primers and hybridization probes were
designed and synthesized by Tib MolBiol GmbH (Berlin,
Germany). PCR was carried out in 96-well plates (Roche
Applied Science; Mannheim, Germany) using 12.5 ng of
genomic DNA as template in a final reaction volume of
5 μl. Reaction mixtures contained 0.5 μM of each pri-
mer, 0.15 μM of SNP-specific hybridization probes and
1 μl of LightCycler 480 Genotyping Master (Taq DNA
polymerase, reaction buffer, 15 mM MgCl2, and a dNTP
mixture with UTP instead of dTTP) (Roche Diagnostics
GmbH, Mannheim, Germany).
The cycling program consisted of 10 minutes of initial
denaturation at 95°C, followed by 35 cycles (rs1333049,
rs2383206, rs2383207, rs10757274, rs10757278) or 40
cycles (rs1333040) of denaturation at 95°C for 5 sec-
onds, annealing at 53°C (rs1333049, rs2383206,
rs2383207), at 59°C (rs1333040) or at 62°C (rs10757274,
rs10757278) for 10 seconds, and extension at 72°C for
10 seconds. After PCR melting curves were generated
by holding the reaction mixture at 95°C for 1 minute,
stepwise lowering of the temperature to 65°C, 55°C and
45°C, holding for 30 seconds at each temperature, low-
ering to 40°C for 2 minutes, followed by continuously
heating to 75°C. Melting curve analyses were conducted
using the LightCycler 480 software according to the
manufacturer’s instructions (Roche Diagnostics GmbH;
Mannheim, Germany).
Statistical analysis
The distribution of genotypes and the allelic frequencies
were investigated and analyzed by alignment to pre-
viously published data of applicable controls. Genotypes
were tested for Hardy-Weinberg equilibrium among MI
cases and controls using a chi-square test with one
degree of freedom. Differences in the genotype distribu-
tion were tested for statistically significance and odds
ratios (ORs) were determined using the 2-way contin-
gency table chi-square test using a freely accessible pro-
gram (http://statpages.org/ctab2x2.html). For all data, the
association was considered to be significant for p < 0.05.
Results
Patients
A total of 976 patients, aged 24 to 65, were included
into the present study to investigate the association
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72.8% of the ACS patients hospitalised with MI were
diagnosed with ST-segment elevation (STEMI), 27.2% of
the patients with non ST-segment elevation (NSTEMI).
Of 976 patients 361 patients (37%) declared a positive
family history of MI, defined as at least one first-degree
relative affected before the age of 60 years, 404 patients
(41.4%) had a negative family history, whereas 211
patients (21.6%) were not aware of another MI case in
their family.
Controls were selected from previously published gen-
otyping data. These data comprised subjects from Eur-
ope which were enrolled for independent studies as
previously described elsewhere [3,4,11]. The baseline
clinical characteristics and procedural parameters of the
study population are presented in Table 1.
Replicated association of six variants on 9p21.3 with
acute MI
Six SNPs on chromosome 9p21.3 were selected for gen-
otyping based on strength of association in previous stu-
dies [3,4,11]. In order to confirm the reported
association of the investigated SNPs with MI, genotyp-
ing data of the overall study cohort were compared to
previously published data of control subjects (Table 2).
All controls were without known history of CAD.
Furthermore, only control cohorts were selected, which
were comparable to the MI cases of the present study
concerning geographic origin (northern and central Eur-
ope), age and wherever applicable, gender.
The rs1333049 genotype distribution and allelic fre-
quencies were compared to the data of the PopGen con-
trols [11]. For analysing the data of rs1333040,
rs10757278, and rs2383207 we used the controls of the
Iceland B collectives [4] and for the analysis of
rs2383206 and rs10757274 the Copenhagen City Heart
Study (CCHS) controls [3]. The genotype distribution in
MI cases and controls did not significantly (P > 0.1)
deviate from the Hardy-Weinberg equilibrium.
A ss h o w ni nt a b l e2 ,as t a t i s t ically significant differ-
ence in the distribution of genotypes of MI cases com-
pared to controls was observed for all analyzed SNPs (p
< 0.0001). Odds ratios determined for the respective
high-risk homozygous alleles were in the range of 1.621
to 2.039. These findings verified the strong association
of the 9p21.3 locus with MI in this large scale study
population of male patients presented with ACS.
Variants on 9p21.3 are associated with a positive family
history of MI
To investigate the association between the sequence var-
iants and a positive family history of MI, patients with at
least one first degree-relative who had suffered from a
premature MI (n = 361) were selected and the genotype
distribution and allelic frequencies for all variants were
analyzed and compared with the data of the correspond-
ing control cohorts (Table 3) and with the data of the
patients without a positive family history (Table 4).
Statistical analyses revealed odds ratios in the range of
1.892 to 2.769 for MI patients with a positive family his-
tory demonstrating a much stronger association than for
the overall cohort of MI patients and therefore a consid-
erable increased risk for MI patients with a family bur-
den of the disease (Figure 1).
These findings could be confirmed comparing MI
patients with a positive family history with patients
without a positive family history for all SNP variants
with the exception of the rs1333040 SNP (Table 4).
These results could also be confirmed in an additional
haplotype analysis (Figure 2). For the haplotypes
GGGGC and AAAAG spanning the rs10757274,
rs2383206, rs2383207, rs10757278, and rs1333049 SNPs
a significant association of a positive vs. a negative
family history could be shown (p = 0.0051 and p =
0.0087 respectively). Adjustment for other cardiovascular
risk factors (smoking, body mass index, hypertension,
diabetes mellitus and hyperlipidemia) revealed no higher
frequencies of the risk variants within the 9p21.3 region
Table 1 Clinical characteristics of the study population
Characteristic Study Population n = 976
ACS – no. (%)
STEMI 711 (72.8)
NSTEMI 266 (27.2)
Age at recruitment – yr 52 ± 8,7
≤ 55 601 (61.6)
Cardiovascular risk factor – no. (%)
Diabetes mellitus 131 (13.4)
Hypertension 507 (51.9)
Hyperlipidaemia 529 (54.2)
Former or current smoker 843 (86.4)
BMI – kg/m
2 28 ± 4.97
BMI ≥ 30 kg/m
2 280 (28.7)
Positive family history of MI – no. (%) 361 (37.0)
Event – no. (%)
Previous MI
> 14 days 99 (10.1)
< 14 days 9 (0.9)
CAD 156 (16.0)
PCI 111 (11.4)
CABG 27 (2.8)
Stroke 14 (1.4)
PAOD 26 (2.6)
Data are shown as mean ± standard deviation; MI myocardial infarction, STEMI
ST-elevation myocardial infarction, NSTEMI non ST-elevation myocardial
infarction, CAD coronary artery disease, PCI percutaneous coronary
intervention, BMI body mass index, CABG coronary artery bypass grafting,
PAOD peripheral artery occlusive disease.
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(data not shown). These findings emphasize this genetic
region as a genetic risk factor for MI independent of
other risk factors.
Discussion
In recent years, genome wide association studies focused
on genomic factors involved in development of CAD
and MI. In these studies and subsequent replication stu-
dies the 9p21.3 locus was found to be the most common
locus associated with CAD and MI. Moreover, in a sub-
sequent study, a strong association of the SNP
rs1333049 representing the 9p21.3 risk variant with the
extent of CAD could be shown [18].
In the present study, we investigated the association of
six previously reported sequence variants representing
the 9p21.3 locus in a large scale study population of
male patients who had suffered from an acute MI. In
this well defined study cohort, the exclusive inclusion of
patients aged ≤ 65 years increased the probability that
genetic factors are involved to a significant degree in the
onset of MI. Moreover, only men were enrolled which
excludes gender specific differences having an influence
on the development of CHD. It is well known that
women develop CHD about 10 years later than men,
probably due to the protective effects of female sex hor-
mones but also due to the different frequency of classi-
cal risk factors such as diabetes, hypertension and
smoking habits [19,20].
Genotyping of the study population showed similar or
even higher high-risk allele frequencies compared to
those in previous studies which reported the association
of 9p21.3 sequence variants with CHD and MI [3,4,11].
Comparison was carried out using previously cited con-
trol subjects from central or northern Europe and with-
out a known history of CAD. Moreover, in the German
PopGen study only men were used as control subjects
[11]. Thus, the selected controls were comparable to the
present MI cohort and therefore justifiably applied in
the presented association analyses. Comparison of the
data with control subjects revealed a statistical signifi-
cant difference in the genotype distribution and allelic
frequencies of all analyzed polymorphisms within the
9p21.3 region. The observed higher odds ratios are
probably due to the much more homogeneity of the
study cohort investigated in the present study. No sig-
nificant difference was observed in the genotype distri-
bution of our MI cases and MI patients from previous
studies. Hence, we confirmed the association of this
locus with MI in the present study cohort. This
Table 2 Association of six variants on 9p21.3: MI study population vs. controls
Variant Controls Risk Allele Frequency MI Cases n = 976 Risk Allele Frequency HW P value OR (95% CI)
rs1333040 b) n = 3532
C/C T/T T: 0.50 C/C T/T T: 0.56 0,993 <0.0001 1.621 (1.317-2.994)
893 889 181 292
rs10757274 c) n = 9053
A/A G/G G: 0.45 A/A G/G G: 0.52 0,075 <0.0001 1.904 (1.570-2.309)
2752 1758 208 253
rs2383206 c) n = 9053
A/A G/G G: 0.47 A/A G/G G: 0.55 0,06 <0.0001 1.867 (1.535-2.272)
2489 1981 183 272
rs2383207 b) n = 3532
A/A G/G G: 0.46 A/A G/G G: 0.55 0,25 <0.0001 2.039 (1.654-2.514)
1016 746 183 274
rs10757278 b) n = 718
A/A G/G G: 0.43 A/A G/G G: 0.52 0,062 <0.0001 1.941 (1.458-2.583)
224 128 211 243
rs1333049 a) n = 999
G/G C/C C: 0.46 G/G C/C C: 0.52 0,233 <0.0001 1.653 (1.280-2.135)
292 205 212 246
Genotype distribution and allelic frequencies of the investigated SNPs on 9p21.3 of the overall study cohort were compared with control data of the PopGen
cohort (a) [11], the Iceland B collective (b) [4] or the Copenhagen City Heart Study (c) [3]. HW: P value for Hardy-Weinberg equilibrium test. P values and Odds
ratios (OR) were calculated for the high-risk homozygous alleles.
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Variant Controls Risk Allele Frequency Positive Family History Risk Allele Frequency P value OR (95% CI)
rs1333040 b) n = 3532
C/C T/T T: 0.50 C/C T/T T: 0.57 <0.0001 1.892 (1.366-2.619)
893 889 60 113
rs10757274 c) n = 9053
A/A G/G G: 0.45 A/A G/G G: 0.56 <0.0001 2.625 (1.922-3.585)
2752 1758 65 109
rs2383206 c) n = 9053
A/A G/G G: 0.47 A/A G/G G: 0.57 <0.0001 2.351 (1.719-3.214)
2489 1981 62 116
rs2383207 b) n = 3532
A/A G/G G: 0.46 A/A G/G G: 0.58 <0.0001 2.570 (1.864-3.543)
1016 746 62 117
rs10757278 b) n = 718
A/A G/G G: 0.43 A/A G/G G: 0.55 <0.0001 2.769 (1.904-4.026)
224 128 67 106
rs1333049 a) n = 999
G/G C/C C: 0.46 G/G C/C C: 0.55 <0.0001 2.232 (1.567-3.180)
292 205 67 105
Genotype distribution and allelic frequencies of the investigated SNPs on 9p21.3 of the study subpopulation with a positive family history compared to control of
the PopGen cohort (a) [11], the Iceland B collective (b) [4] or the Copenhagen City Heart Study (c) [3]. P values and Odds ratios (OR) were calculated for the high-
risk homozygous alleles.
Table 4 Association of six variants on 9p21.3: MI study subpopulation with a positive family history vs. MI study
subpopulation with a negative family history
Variant Negative Family History
n = 404
Risk Allele Frequency Positive Family History
n = 361
Risk Allele Frequency P value OR (95% CI)
rs1333040
C/C T/T T: 0.53 C/C T/T T: 0.57 0.102 1.426(0.932-2.180)
81 107 60 113
rs10757274
A/A G/G G: 0.48 A/A G/G G: 0.56 0.002 1.940(1.269-2.964)
96 83 65 109
rs2383206
A/A G/G G: 0.51 A/A G/G G: 0.57 0.015 1.703(1.108-2.618)
81 89 62 116
rs2383207
A/A G/G G: 0.51 A/A G/G G: 0.58 0.016 1.696(1.103-2.608)
80 89 62 117
rs10757278
A/A G/G G: 0.47 A/A G/G G: 0.55 0.003 1.923(1.256-2.944)
96 79 67 106
rs1333049
G/G C/C C: 0.48 G/G C/C C: 0.55 0.003 1.896(1.241-2.898)
98 81 67 105
Genotype distribution and allelic frequencies of the investigated SNPs on 9p21.3 of the study subpopulation with a positive family history were compared with
the study subpopulation with a negative family history. P values and Odds ratios (OR) were calculated for the high-risk homozygous alleles.
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tor in the pathogenesis of CAD and MI.
Having replicated the association of all investigated
SNPs with MI, patients having definitively presented
with positive family history of MI were selected and
compared to the corresponding control cohorts or a
subpopulation of patients with a definitively negative
family history. For the accuracy of this analysis, patients
who provided no information on a family history of MI
were excluded. This analysis revealed a significantly
stronger association in patients having presented with a
positive family history of MI than in the overall cohort
of MI patients with calculated odds ratios within the
range of 1.892 to 2.769.
Classification according to a positive family history
provides an improved risk prediction for the patients. In
fact, the increased risk of carriers of the homozygous
risk alleles and a positive family history is comparable to
the increased risk of hypertensive patients (OR 1.91),
patients with diabetes mellitus (OR 2.37) or current
smokers (OR 2.87) calculated in a large case-control
study of acute MI in 52 countries [21].
Conclusions
To our knowledge the present study is the first one to
analyse the association of all six 9p21.3 SNPs with acute
MI in relation to a positive family history. Indeed, few
other studies reported the association with CAD after
classification of patients according to their family history.
However, our study differs from the others in the origin
of the patients, in the strict inclusion criteria and in the
larger number of patients. Moreover, the quantity of ana-
lyzed sequence variants in the present study was higher.
Our findings made evident the correlation between
high-risk variants on the 9p21.3 locus and male patients
with acute MI and a positive family history. Over the
past few years, risk evaluation has exclusively been per-
formed on the prevalence of classical risk factors such
as age and gender, LDL-cholesterol, hypertension, dia-
betes mellitus, smoking habits, diet, a family history and
physical activity [22,23]. The findings of the present
study may help to improve risk assessment and early
prevention particularly for patients with a positive family
history of CAD when 9p21.3 sequence variants are taken
into account.
Limitations of the study
One limitation of the study is the lack of an own con-
trol group. Using previous reported data about the
allelic distribution of SNP’s will be of a limited bias
due to the fact, that thousands of chromosomes where
analysed in previous reported studies. Another limita-
tion is that not a consistent control group could be
used for comparison.
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